A Phase 2, Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 Administered by Subcutaneous Injection in Patients With Heterozygous Familial Hypercholesterolemia.
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2017
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.
- 07 Nov 2016 New trial record